Posted on April 11, 2018 by Sitemaster
According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficacy, lutetium-177, outcome, Phase III, pivotal, PSMA-617, safety, trial | 4 Comments »
Posted on April 6, 2018 by Sitemaster
We have known for some time that taking abiraterone acetate (Zytiga) with food (as opposed to on an empty stomach) might well allow patients to be able to take significantly lower doses of this product and gain the same clinical benefit as is currently known to be beneficial from taking 1,000 mg/day when fasting. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, dose, food, low, standard, with, without | 5 Comments »
Posted on April 2, 2018 by Sitemaster
It wouldn’t be wise to expect anything big in a hurry, but it is now clear that the Sanpower Group, which acquired Dendreon about a year ago, has serious plans to do things that the “old Dendreon” never did to optimize the potential of sipuleucel-T (Provenge). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: access, availability, Provenge, sipuleucel-T | 2 Comments »
Posted on March 26, 2018 by Sitemaster
In an important decision announced late on Friday last week, the Centers for Medicare & Medicaid Services (CMS) announced that it had agreed to cover costs associated with genetic/genomic testing for Medicare patients with many advanced forms of cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: approval, coverage, genetic, genomic, next generation, NGS, sequencing, test | 1 Comment »
Posted on February 15, 2018 by Sitemaster
Yesterday afternoon the US Food & Drug Administration (FDA) approved apalutamide — which will have the brand name Erleada — for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, approval, Erleada, SPARTAN | Leave a comment »
Posted on February 9, 2018 by Sitemaster
So at the Genitourinary Cancers Symposium in San Francisco today we were presented with full reports on the SPARTAN trial and the PROSPER trial by Drs. Eric Small and Maha Hussain, respectively. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-resistant, enzalutamide, nmCRPC, non-metastatic | 6 Comments »
Posted on February 6, 2018 by Sitemaster
So we now have news reports and abstracts telling us what the top-line results of the SPARTAN trial and the PROSPER trial are in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-resistant, enzalutamide, nmCRPC, non-metastatic, PROSPER, SPARTAN | 17 Comments »
